Corrigenda

In [1], IL-1 β is erroneously named IL-1 α on several occasions in the text.

IL-1 β is used correctly in the abstract (p. 168) and in the relevant figure heading (Fig 5a, p. 173).

IL-1 α is incorrectly used on seven (7) occasions throughout the paper:

- p 169, Top left column (Introduction), line 3.
- p 171, Bottom right column (Results), line 40.
- p 172, Bottom right column (Results), line 1.
- p 173, Bottom right column (Results), line 4.
- p 173, Figure legend, figure 5.
- p 175, Center left column (Discussion), line 26.
- p 175, Top right column (Discussion), line 3.

IL-1 α should be substituted with IL-1 β in all these occurrences.

In [1], an extra comma was introduced in the keywords list: 'multiple organ dysfunction, syndrome (MODS)'. This is incorrect and should read 'multiple organ dysfunction syndrome (MODS)'.

We apologize for these errors.

Reference

1 Sandvik A, Wang YY, Morton HC, Aasen AO, Wang JE, Johansen F.-E. Oral and systemic administration of β -glucan protects against lipopolysaccharide-induced shock and organ injury in rats. Clin Exp Immunol 2007; **148**:168–177.